Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Labcorp Launches GFAP Test: A Crucial Tool for Early Detection of Neurodegenerative Conditions and Neurological Trauma

NextEdge Admin

15 Apr 2024

2 min 49 sec

Labcorp, a leading provider of advanced laboratory services, has unveiled the nation’s premier test for glial fibrillary acidic protein (GFAP), a pivotal blood-based biomarker crucial for the early identification of neurodegenerative disorders and neurological injuries.

This groundbreaking GFAP test, the first of its kind available commercially nationwide, presents physicians with a streamlined approach to gauging the presence and advancement of neurodegenerative ailments like Alzheimer’s disease, multiple sclerosis, glioblastoma, as well as injuries such as traumatic brain injury (TBI). Augmenting Labcorp’s extensive neurology portfolio, which encompasses biomarker tests for neurofilament light chain (NfL), pTau181, pTau217, and beta amyloid 42/40, this innovative test underscores Labcorp’s commitment to advancing diagnostic capabilities in neurology.

Dr. Brian Caveney, Labcorp’s chief medical and scientific officer, remarked, “The debut of the GFAP biomarker test is a momentous achievement for Labcorp, reinforcing our prominence in the swiftly evolving domain of blood-based biomarkers for neurodegenerative disorders. Our diverse portfolio underscores our dedication to furnishing physicians with state-of-the-art technology to assess and manage neurodegeneration, ultimately enhancing patient care.”

The GFAP test harnesses highly sensitive immunoassay technology to quantify the presence of GFAP from a simple blood draw, facilitating convenient testing in hospitals, physician offices, or any of Labcorp’s vast network of over 2,000 patient service centers nationwide.

GFAP, predominantly found in the brain’s supportive astrocytes, is released into the bloodstream by these cells in the context of neurodegenerative conditions or injuries, offering a straightforward means to assess brain injury and disease. Extensively researched, GFAP serves as a valuable early-stage indicator of neurological damage.

Labcorp stands as a global leader in delivering innovative and comprehensive laboratory services, empowering healthcare professionals, pharmaceutical companies, researchers, and patients alike to make informed and confident decisions.